Join Us In Improving the
Lives of Patients with Cancer

Company Overview

Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of oral, GPCR-targeted small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways in difficult-to-treat cancers.

Teon’s rich pipeline includes a novel small molecule, cannabinoid CB2 receptor antagonist acting as a novel immune response modifier, and an antagonist of the A2B receptor in the adenosine pathway.

Teon initiated a Phase 1/2 trial in 2022 evaluating TT-816, a cannabinoid CB2 antagonist, as a monotherapy and in combination with Merck’s KEYTRUDA® (pembrolizumab); and a Phase 1/2 trial evaluating TT-702, an A2B receptor antagonist in 2021.

The highly accomplished scientific leadership team are experts in tumor metabolism, cell signaling and GPCR therapeutic design.

Teon completed its $30M Series A financing round in February 2021.


Why Invest?

We are on a mission to be the undisputed leader in small molecule tumor microenvironment therapeutics. We’re changing cancer care as we know it today.

Teon’s goal is to develop once-daily, oral medications to treat more patients with better outcomes allowing patients to spend time on what matters most.

Demonstrated Expertise

  • World-class drug design, biology & chemistry of G-protein coupled receptors (GPCRs)
  • Our team members have an average of 20+ years’ experience in biotech & Big Pharma

Impeccable Science Addressing Untapped Pathways

  • Targeting unexploited metabolic pathways with initial focus on GPCRs​
  • First- and best-in-class small molecules​​ protected by strong IP

Impactful Value Drivers

  • Lead Molecule Milestones: TT-816 Phase 1/2 monotherapy initiated in 2022 and combo with Merck’s Keytruda initiated 2023; TT-702 Phase 1/2a read-out back-half 2023.

Contact Us

We’d love to connect with you on Teon’s work and mission. Please contact us if you’re interested in learning more.

Latest News